Información del artículo
El diagnóstico del síndrome del canal carpiano, frecuente, rara vez va más allá de un estudio clínico y electromiográfico. Presentamos el caso de una mujer de 60 años diagnosticada de amiloidosis AL primaria sistémica muchos años después de que se hubiera manifestado el síndrome del canal carpiano.
Palabras clave:
Síndrome del canal carpiano
Amiloidosis
Amiloidosis AL primaria sistémica
The diagnosis of common carpal tunnel syndrome, usually relies only on clinical grounds and electromyographic study. We present a 60-year-old woman who was diagnosed with systemic primary AL amyloidosis many years after the carpal tunnel syndrome had begun.
Key words:
Carpal tunnel syndrome
Amyloidosis
Systemic primary AL amyloidosis
El Texto completo está disponible en PDF
Bibliografía
[1.]
D.C. Seldin, M. Skinner.
Arthritis accompanying systemic diseases.
7.a ed, pp. 1697-1704
[2.]
R.W. Sims, M.N. Prout, A.S. Cohen.
The epidemiology of AL and AA amyloidosis.
Bailliere Clin Rheumatol, 8 (1994), pp. 627-636
[3.]
R.S. Abraham, R.J. Clark, S.C. Bryant, J.F. Lymp, T. Larson, R.A. Kyle, et al.
Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma.
Clin Chem, 48 (2002), pp. 655-657
[4.]
M.T. Elghetany, A. Saleem.
Methods for staining amyloid in tissues: a review.
Stain Technol, 63 (1988), pp. 201-212
[5.]
E. Arbustini, P. Morbini, L. Verga, G. Merlini.
Light and electron microscopy immunohistochemical characterization of Amyloid deposits.
Amyloid - Int J Exp Clin Invest, 4 (1997), pp. 157-170
[6.]
A. Lim, J. Wally, M.T. Walsh, M. Skinner, C.E. Costello.
Identification and localization of a cysteinyl pottranslational modification in an amyloidogenic kappa 1 light chain protein by electrospray ionization and matrix-assisted laser desoption/desonisation mass spectrometry.
Anal Biochem, 295 (2001), pp. 45-56
[7.]
M. Skinner, J. Anderson, R. Simms, R. Falk, M. Wang, C. Libbey, et al.
Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.
Am J Med, 100 (1996), pp. 290-298
[8.]
Resnick, G. Niwayama.
Diagnosis of bone and joint disorders.
2.a ed., Sauders, (1998),
[9.]
I.l. Van Gameren, B.P.C. Hazenberg, P.L. Jager, J.W. Smit, E. Vallenga.
AL amyloidosis treated with induction chemotherapy with VAD followed by hight dose melphalan and autologous stem cell transplantation.
Amyloid: J Protein Folding Disorders, 9 (2002), pp. 165-174
[10.]
M.B. Pepys, J. Herbert, W.L. Hutchinson, G.A. Tennent, H.J. Lachman, J.R. Gallimore, et al.
Targeted pharmalogical depletion of serum amyloid P component for treatment of human amyloidosis.
Nature, 417 (2002), pp. 254-259
Copyright © 2007. Elsevier España S.L Barcelona
